Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine

Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine
Panacea Pharmaceuticals has completed patient enrollment in a Phase 1 clinical trial testing its PAN-301-1 vaccine as a treatment for prostate cancer that has failed to respond to other therapies. The multi-center trial (NCT03120832) is looking at the vaccine’s ability to provoke an immune response in prostate cancer patients who experienced a rise in their PSA levels after surgery

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *